The biologic drug interferon-alpha can benefit patients with blood cancers called myeloproliferative neoplasms by forcing mutant blood stem cells to become shorter-lived white blood cells, according to a study by Weill Cornell Medicine investigators. Because the broad activity of interferon-alpha can induce significant side effects,

New US Medicare pricing policies could reshape global pharmaceutical markets, potentially driving up prices and delaying medicine launches worldwide, study suggests. A new modelling study published in The Lancet suggests that US Medicare's new 'Most-Favoured-Nation' pricing policy [1], which ties what Medicare pays for medicines to prices charged in other high-income countries,

Investigators at Cedars-Sinai Health Sciences University used an experimental drug to reverse the effects of systemic sclerosis, a serious autoimmune disease. The study, conducted in a laboratory, was published in JCI Insight.

Systemic sclerosis, also called scleroderma, is a chronic, life-threatening condition that scars the skin, lungs, heart and other organs.

Pushing the accelerator and the brake at the same time is rarely a good idea. But researchers at the University of Gothenburg are using this approach to treat leukemia. A new drug forces cancer cells to keep working hard even though they have run out of energy. The first study in mice shows very promising results.

A team led by Leif Eriksson at the University of Gothenburg and Boaz Tirosh at Case Western Reserve University in Cleveland has developed a new treatment for acute myeloid leukemia (AML).

Cyclopropanes are organic chemistry’s smallest rings. Three carbon atoms are joined in a triangle, creating a compact and unusually strained structure. Despite - or partly because of - this unusual geometry, cyclopropanes are found in many biologically active natural products and have important applications in medicines and drug discovery, from antidepressants to antibiotics and antiviral research.

Liver cancer is difficult to treat because tumors vary greatly from patient to patient. Researchers at the University of Basel have captured this diversity by creating a collection of mini-tumors, which they use to systematically search for new treatment options. They tested more than 1,600 compounds using these organoids and used the results to develop promising drug combinations.

Researchers today announce AdaptiveFlow, an AI-informed platform that can virtually screen billions of drug-like molecules with a 1,000-fold reduction in computational costs over existing methods. Developed and validated by scientists from St. Jude Children’s Research Hospital, University of Pavia, Dana Farber Cancer Institute and Harvard Medical School, AdaptiveFlow allows prohibitively expensive ultra-large virtual drug screens to be done routinely. The open-source platform was published in Nature Biotechnology.